Volver a Agenda
Session Chair(s)
Andrew Satlin
Chief Medical Officer
Intra-Cellular Therapies, United States
Learning Objective : Discuss what challenges have arisen from early and late clinical development; Recognize lessons learned from past trials and what changes could be made if redesigned.
Speaker(s)
Bayesian Adaptive Trial Design: A New Approach for Phase 2 Clinical Trials in Alzheimer’s Disease
Andrew Satlin
Intra-Cellular Therapies, United States
Chief Medical Officer
Current Landscape of Alzheimer's Clinical Trials: Lessons From the Recent Failures in Phase 3
Reisa A. Sperling, MD
Brigham and Women's Hospital , United States
Director, Center for ALZ Rsrch & Treatment; Prof, Neurology, Harvard Medical
Advancement of Diagnostics for Patient Stratification in Alzheimer's Disease Drug Trials
Johan Luthman
Merck & Co., Inc., United States
Senior Program Leader, Early Development Neuroscience & Opthalmology R&D
¿Tiene una cuenta?